Wall Street Zen Downgrades Definium Therapeutics (NASDAQ:DFTX) to Sell

Definium Therapeutics (NASDAQ:DFTX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other research firms also recently weighed in on DFTX. Needham & Company LLC lifted their target price on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, June 23rd. Stifel Nicolaus increased their price target on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Robert W. Baird raised their price objective on shares of Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, June 23rd. Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Finally, Oppenheimer set a $60.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $55.00.

Definium Therapeutics Price Performance

NASDAQ:DFTX opened at $46.14 on Friday. Definium Therapeutics has a 52 week low of $8.70 and a 52 week high of $49.70. The stock’s fifty day moving average is $37.89 and its two-hundred day moving average is $25.94. The stock has a market capitalization of $4.60 billion, a price-to-earnings ratio of -13.45 and a beta of 2.23. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Research analysts anticipate that Definium Therapeutics will post -2.27 EPS for the current year.

Insider Activity

In other news, CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. This represents a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert Barrow sold 29,208 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the transaction, the chief executive officer owned 1,098,246 shares in the company, valued at approximately $49,454,017.38. The trade was a 2.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 48,096 shares of company stock worth $2,165,763 over the last three months. Insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DFTX. Commodore Capital LP lifted its holdings in shares of Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after purchasing an additional 475,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Definium Therapeutics by 11.0% in the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock valued at $23,732,000 after buying an additional 198,878 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Definium Therapeutics by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock valued at $36,563,000 after acquiring an additional 24,349 shares during the last quarter. UBS Group AG raised its stake in shares of Definium Therapeutics by 7.3% during the third quarter. UBS Group AG now owns 551,809 shares of the company’s stock worth $6,506,000 after purchasing an additional 37,364 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new position in Definium Therapeutics during the 3rd quarter worth $4,337,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.